US blacklist of Chinese pharma firms unlikely to impact costs, analysts say

Analysts believe that US efforts to blacklist Chinese pharmaceutical firms, including WuXi AppTec, will have minimal impact due to cost advantages. Despite the US Department of Defense adding WuXi AppTec to an updated list of "Chinese military companies," multinational drug makers are expected to continue prioritizing Chinese manufacturing for cost efficiency. Previous legislative attempts to ban contracts with similar firms also saw company names removed before enactment, suggesting a continued preference for cost-effective production in the healthcare sector. AI

IMPACT Minimal direct impact on AI operators; focuses on supply chain and regulatory policy in the pharmaceutical sector.

RANK_REASON The article discusses analyst opinions on the impact of a regulatory action, rather than reporting on the action itself or a new development.

Read on SCMP — Tech →

• BGI Group
• Complete Genomics
• Cui Cui
• Jefferies
• MGI Tech
• US Department of Defense
• WuXi AppTec
• WuXi Biologics

• policy
• other

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →